Jazz working with MD Anderson to evaluate AML treatments

Roche’s MabThera approved in Europe for pemphigus vulgaris
Credit: Shutterstock.com/ Piotr Adamowicz

Jazz Pharmaceuticals is working with the University of Texas MD Anderson Cancer Centre to evaluate therapies for multiple hematologic malignancies – including acute myeloid leukaemia (AML) and myelodysplastic syndromes.

The five-year agreement brings together MD Anderson’s translational medicine and clinical research capabilities with Jazz’s haematology/oncology portfolio – including its FDA-approved medicines as well as current and potential future investigational therapies.

“This collaboration represents a significant opportunity to efficiently develop innovative therapies and therapeutic combinations,” said Tapan Kadia, associate professor of Leukaemia at MD Anderson.

“Our aim is to always provide leading-edge care for our leukaemia patients, and it is our hope that this joint effort will result in new treatment solutions.”

The two organisations will pursue research opportunities in areas of high unmet need. The initial focus of the collaboration is to evaluate and generate additional data for Vyxeos liposome for injection, in new patient populations and in combination with other therapies.